189 related articles for article (PubMed ID: 32934708)
1. Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and genetic characterization.
Gomez-Macias GS; Molinar-Flores G; Lopez-Garcia CA; Santuario-Facio S; Decanini-Arcaute H; Valero-Elizondo J; Treviño-Alvarado V; Ortiz-Lopez R; Dono A; Esteban-Zubero E; Alatorre-Jimenez MA; Garza CV; Peña-Curiel O; Cardona-Huerta S
Oncol Lett; 2020 Nov; 20(5):140. PubMed ID: 32934708
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
[TBL] [Abstract][Full Text] [Related]
3. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
4. Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy.
Castaneda CA; Mittendorf E; Casavilca S; Wu Y; Castillo M; Arboleda P; Nunez T; Guerra H; Barrionuevo C; Dolores-Cerna K; Belmar-Lopez C; Abugattas J; Calderon G; De La Cruz M; Cotrina M; Dunstan J; Gomez HL; Vidaurre T
World J Clin Oncol; 2016 Oct; 7(5):387-394. PubMed ID: 27777881
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors.
Baram T; Erlichman N; Dadiani M; Balint-Lahat N; Pavlovski A; Meshel T; Morzaev-Sulzbach D; Gal-Yam EN; Barshack I; Ben-Baruch A
Cells; 2021 Jun; 10(6):. PubMed ID: 34201054
[TBL] [Abstract][Full Text] [Related]
7. Tumor infiltrating lymphocytes profile and response in neoadjuvant chemotherapy-treated triple-negative breast carcinoma patients.
Ray D; Gupta SD; De A; Jain P; Bhattacharya NK; Biswas PK
J Cancer Res Ther; 2022; 18(6):1782-1788. PubMed ID: 36412444
[TBL] [Abstract][Full Text] [Related]
8. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
9. Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer.
Song IH; Heo SH; Bang WS; Park HS; Park IA; Kim YA; Park SY; Roh J; Gong G; Lee HJ
Cancer Res Treat; 2017 Apr; 49(2):399-407. PubMed ID: 27488875
[TBL] [Abstract][Full Text] [Related]
10. Predictive and Prognostic Value of Tumor- Infiltrating Lymphocytes for Pathological Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer.
Mohammed AA; Mostafa Elsayed F; Algazar M; Rashed HE
Gulf J Oncolog; 2022 Jan; 1(38):53-60. PubMed ID: 35156645
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
[TBL] [Abstract][Full Text] [Related]
13. YAP1/MMP7/CXCL16 axis affects efficacy of neoadjuvant chemotherapy via tumor environment immunosuppression in triple-negative breast cancer.
Yuan JQ; Zhang KJ; Wang SM; Guo L
Gland Surg; 2021 Sep; 10(9):2799-2814. PubMed ID: 34733729
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death protein 1 is a marker for neoadjuvant chemotherapy response in triple-negative breast cancer.
Gaui MFD; Amendola LC; Quintella DC; Canedo N; Bonomo A
Rev Assoc Med Bras (1992); 2023; 69(9):e20230276. PubMed ID: 37729362
[TBL] [Abstract][Full Text] [Related]
15. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
[TBL] [Abstract][Full Text] [Related]
16. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
Wang K; Shen T; Siegal GP; Wei S
Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
[TBL] [Abstract][Full Text] [Related]
17. Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Herrero-Vicent C; Guerrero A; Gavilá J; Gozalbo F; Hernández A; Sandiego S; Algarra MA; Calatrava A; Guillem-Porta V; Ruiz-Simón A
Ecancermedicalscience; 2017; 11():759. PubMed ID: 28900472
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of tumor‑infiltrating lymphocytes in residual tumor tissue from patients with triple‑negative breast cancer following neoadjuvant chemotherapy: A systematic review and meta‑analysis.
Cao B; Zhang Z; Wang C; Lv X
Oncol Lett; 2023 Oct; 26(4):441. PubMed ID: 37664648
[TBL] [Abstract][Full Text] [Related]
19. Tumor infiltrating CD8
Mella M; Kauppila JH; Karihtala P; Lehenkari P; Jukkola-Vuorinen A; Soini Y; Auvinen P; Vaarala MH; Ronkainen H; Kauppila S; Haapasaari KM; Vuopala KS; Selander KS
Oncoimmunology; 2015 Jun; 4(6):e1002726. PubMed ID: 26155410
[TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating lymphocytes and CD8
Vihervuori H; Autere TA; Repo H; Kurki S; Kallio L; Lintunen MM; Talvinen K; Kronqvist P
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3105-3114. PubMed ID: 31562550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
